Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Stanford University
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
University of Michigan Rogel Cancer Center
Gilead Sciences
St. Jude Children's Research Hospital
AIDS Malignancy Consortium
Jonsson Comprehensive Cancer Center
Weill Medical College of Cornell University
Swiss Cancer Institute
Weill Medical College of Cornell University
Virginia Commonwealth University
Milton S. Hershey Medical Center
National Institutes of Health Clinical Center (CC)
Singapore General Hospital
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Augusta University
Amgen
National Cancer Institute (NCI)
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
NYU Langone Health
University of California, San Francisco
M.D. Anderson Cancer Center
Millennium Pharmaceuticals, Inc.
Mayo Clinic